Neuroscience Stocks
Precision engineering of the central nervous system encompasses a spectrum of drug developers, medical device manufacturers, and royalty aggregators focused on neurological and psychiatric pathologies. Revenue models are primarily binary, driven by rigorous clinical trial data or the adoption of neuro-navigational hardware and implantable sensing technologies.
As of Oct 23, 2026, Neuroscience has 134 US-listed companies worth $3.2T combined. The median member moved +0.8% over the past week; DFTX led among the 25 largest at +11.1% and RGC trailed at -20.0%.
Companies in Neuroscience
- LLY – Eli Lilly and Company, $1.1T
- JNJ – Johnson & Johnson, $645B
- ABBV – AbbVie Inc, $505B
- NVS – Novartis AG ADR, $287B
- BMY – Bristol-Myers Squibb Company, $129B
- MDT – Medtronic PLC, $122B
- SYK – Stryker Corporation, $118B
- TAK – Takeda Pharmaceutical Co Ltd ADR, $64.7B
- TEVA – Teva Pharma Industries Ltd ADR, $46B
- BIIB – Biogen Inc, $37B
- NBIX – Neurocrine Biosciences Inc, $14.6B
- JAZZ – Jazz Pharmaceuticals PLC, $13.9B
- PEN – Penumbra Inc, $12.8B
- AXSM – Axsome Therapeutics Inc, $7.6B
- ALKS – Alkermes Plc, $7.4B
- IONS – Ionis Pharmaceuticals Inc, $7.3B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- PTCT – PTC Therapeutics Inc, $5.3B
- RGC – Regencell Bioscience Holdings Ltd, $4.8B
- DFTX – Definium Therapeutics, Inc., $4.4B
- ITGR – Integer Holdings Corp, $4.3B
- LIVN – LivaNova PLC, $4.3B
- AMLX – Amylyx Pharmaceuticals Inc, $3.6B
- XENE – Xenon Pharmaceuticals Inc, $3.5B
- ACAD – ACADIA Pharmaceuticals Inc, $3.5B
- DNLI – Denali Therapeutics Inc, $3B
- HRMY – Harmony Biosciences Holdings, $2.1B
- INSP – Inspire Medical Systems Inc, $2B
- ZBIO – Zenas BioPharma, Inc. Common Stock, $1.8B
- BHVN – Biohaven Ltd., $1.8B
- STOK – Stoke Therapeutics Inc, $1.7B
- QURE – Uniqure NV, $1.6B
- CMPS – Compass Pathways Plc, $1.6B
- KRSA – Korsana Biosciences, Inc., $1.5B
- RAPP – Rapport Therapeutics, Inc. Common Stock, $1.3B
- GHRS – GH Research PLC, $1.3B
- LBRX – LB Pharmaceuticals Inc Common Stock, $1.2B
- LTGO – Latigo Biotherapeutics, Inc. Common Stock, $1.1B
- IART – Integra LifeSciences Holdings, $1B
- SPTX – Seaport Therapeutics, Inc. Common Stock, $986M
- ANRO – Alto Neuroscience, Inc., $956M
- MGTX – MeiraGTx Holdings PLC, $955M
- CBLL – CeriBell, Inc, $888M
- HELP – Cybin Inc., $799M
- ANNX – Annexon Inc, $726M
- COLL – Collegium Pharmaceutical Inc, $701M
- DRUG – Bright Minds Biosciences Inc, $506M
- BWAY – Brainsway Ltd, $474M
- ARVN – Arvinas Inc, $472M
- OCS – Oculis Holding AG Ordinary shares, $461M
- MPLT – MapLight Therapeutics, Inc. Common Stock, $458M
- OVID – Ovid Therapeutics Inc, $441M
- PRTA – Prothena Corporation plc, $435M
- NPCE – Neuropace Inc, $435M
- NGNE – Neurogene Inc, $431M
- RLMD – Relmada Therapeutics Inc, $347M
- MOBI – Mobia Medical, Inc. Common Stock, $287M
- CLPT – Clearpoint Neuro Inc, $277M
- VNDA – Vanda Pharmaceuticals Inc, $273M
- CTNM – Contineum Therapeutics, Inc. Class A Common Stock, $266M
- ACIU – AC Immune Ltd, $256M
- LCTX – Lineage Cell Therapeutics Inc, $251M
- LXEO – Lexeo Therapeutics, Inc. Common Stock, $217M
- CAMP – CAMP4 THERAPEUTICS CORPORATION, $215M
- ALEC – Alector Inc, $214M
- ACOG – Alpha Cognition Inc, $192M
- PEPG – PepGen Ltd, $166M
- NGEN – NervGen Pharma Corp., $166M
- QTRX – Quanterix Corp, $163M
- STIM – Neuronetics Inc, $162M
- TLSA – Tiziana Life Sciences Ltd, $144M
- ABOS – Acumen Pharmaceuticals Inc, $143M
- AVXL – Anavex Life Sciences Corp, $121M
- VYGR – Voyager Therapeutics Inc, $117M
- COYA – Coya Therapeutics, Inc. Common Stock, $116M
- SPRB – Spruce Biosciences, Inc. Common Stock, $116M
- NRXP – NRX Pharmaceuticals Inc, $113M
- NERV – Minerva Neurosciences Inc, $112M
- HYPR – Hyperfine Inc, $98.7M
- PLYX – Polaryx Therapeutics, Inc. Common Stock, $98.2M
- IMUX – Immunic Inc, $95.4M
- NMRA – Neumora Therapeutics, Inc., $89.4M
- CGTX – Cognition Therapeutics Inc, $89.1M
- ECOR – Electrocore LLC, $87.6M
- NRXS – Neuraxis, Inc., $87M
- PMN – ProMIS Neurosciences Inc., $74.3M
- MNOV – MediciNova Inc, $73.8M
- GANX – Gain Therapeutics Inc, $71.6M
- ATHE – Alterity Therapeutics Ltd, $66.8M
- CING – Cingulate Inc, $63.4M
- INMB – INmune Bio Inc, $53.6M
- LONA – LeonaBio, Inc., $49M
- CLNN – Clene Inc., $47M
- SER – Serina Therapeutics Inc, $45.5M
- ANVS – Annovis Bio Inc, $42.3M
- GRCE – Grace Therapeutics, Inc., $41M
- CRVO – CervoMed Inc., $35.4M
- IRLA – IRulya Therapeutics Inc., $35M
- QNCX – Quince Therapeutics, Inc., $32.3M
- MIRA – MIRA Pharmaceuticals, Inc. Common Stock, $28M
- AYTU – Aytu BioScience Inc, $21.3M
- PBM – Psyence Biomedical Ltd. Common Shares, $19.1M
- NEUP – Neuphoria Therapeutics Inc, $18.8M
- NCEL – NewcelX Ltd., $16.5M
- AIFF – Firefly Neuroscience, Inc., $16M
- QNTM – Quantum BioPharma Ltd., $14.6M
- KTTA – Pasithea Therapeutics Corp, $14M
- BIVI – Biovie Inc, $11.9M
- PASG – Passage Bio Inc, $11.9M
- AEON – AEON Biopharma, Inc., $11.6M
- NMTC – Neuroone Medical Technologies Corp, $9.7M
- BCLI – Brainstorm Cell Therapeutics Inc, $9.2M
- VTGN – VistaGen Therapeutics Inc, $8.9M
- NKGN – NKGen Biotech, Inc. Common Stock, $7.8M
- INM – InMed Pharmaceuticals Inc, $7.6M
- ALZN – Alzamend Neuro Inc, $6.5M
- RVPH – Reviva Pharmaceuticals Holdings Inc., $6.5M
- ENVB – Enveric Biosciences Inc, $6.2M
- NRSN – Neurosense Therapeutics Ltd, $5.8M
- ADXN – Addex Therapeutics Ltd, $5.4M
- AMIX – Autonomix Medical, Inc. Common Stock, $4.9M
- XTLB – XTL Biopharmaceuticals Ltd ADR, $4.6M
- NXL – Nexalin Technology Inc., $3.8M
- NIKI – Niki BioSolutions, Inc., $3.7M
- JUNS – Jupiter Neurosciences, Inc. Common Stock, $3.4M
- CMND – Clearmind Medicine Inc. Common Shares, $3.3M
- VCNX – Vaccinex Inc, $2.8M
- SILO – Silo Pharma Inc, $2.5M
- BTAI – BioXcel Therapeutics Inc, $2.3M
- OGEN – Oragenics Inc, $1.9M
- PTIX – Protagenic Therapeutics, $1.4M
- PXMD – PaxMedica Inc. Common Stock, $88,385
- TRVN – Trevena Inc, $57,010
- VAXX – Vaxxinity Inc, $12,678